It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors.
EBTATE is used in Precision Medicine for Targeted Radionuclide Therapy. The key feature of this technology is the appendage of Evans blue to the targeting radiopharmaceutical.
EB binds reversibly to serum albumin to enhance the radiotherapeutic time window with longer circulation half-life and increase tumor uptake/retention to improve therapeutic outcome.
Molecular Targeting Technologies is a privately held, clinical stage biotechnology company, developing targeted radiotherapeutics and diagnostics for rare cancers.
MTTI has received an exclusive worldwide license from the National Institutes of Health to commercialize selected targeted radiopharmaceuticals covered by their Evans blue platform technology patents.
This transformative technology has potential applications for other types of cancer patients overexpressing somatostatin receptor type 2 (SSTR2), such as Hürthle Cell Thyroid Carcinoma.
The company is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical therapy assets to improve human health, reduce healthcare costs and reward stakeholders.
It contracts with ClinSmart as a Clinical Research Organization (Newtown, PA). MTTI expects to orchestrate multiple clinical trials in 2021.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT